Antiangiogenesis Enhances Intratumoral Drug Retention
Authors:
Open Access
- 31 March 2011
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 71 (7) , 2675-2685
Abstract
The tumor vasculature delivers nutrients, oxygen, and therapeutic agents to tumor cells. Unfortunately, the delivery of anticancer drugs through tumor blood vessels is often inefficient and can constitute an important barrier for cancer treatment. This barrier can sometimes be circumvented by antiangiogenesis-induced normalization of tumor vasculature. However, such normalizing effects are transient; moreover, they are not always achieved, as shown here, when 9L gliosarcoma xenografts were treated over a range of doses with the VEGF receptor-selective tyrosine kinase inhibitors axitinib and AG-028262. The suppression of tumor blood perfusion by antiangiogenesis agents can be turned to therapeutic advantage, however, through their effects on tumor drug retention. In 9L tumors expressing the cyclophosphamide-activating enzyme P450 2B11, neoadjuvant axitinib treatment combined with intratumoral cyclophosphamide administration significantly increased tumor retention of cyclophosphamide and its active metabolite, 4-hydroxycyclophosphamide. Similar increases were achieved using other angiogenesis inhibitors, indicating that increased drug retention is a general response to antiangiogenesis. This approach can be extended to include systemic delivery of an anticancer prodrug that is activated intratumorally, where antiangiogenesis-enhanced retention of the therapeutic metabolite counterbalances the decrease in drug uptake from systemic circulation, as exemplified for cyclophosphamide. Importantly, the increase in intratumoral drug retention induced by neoadjuvant antiangiogenic drug treatment is shown to increase tumor cell killing and substantially enhance therapeutic activity in vivo. Thus, antiangiogenic agents can be used to increase tumor drug exposure and improve therapeutic activity following intratumoral drug administration, or following systemic drug administration in the case of a therapeutic agent that is activated intratumorally. Cancer Res; 71(7); 2675–85. ©2011 AACR.Keywords
All Related Versions
This publication has 53 references indexed in Scilit:
- Development of a Novel Tumor-Targeted Vascular Disrupting Agent Activated by Membrane-Type Matrix MetalloproteinasesCancer Research, 2010
- Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trialThe Lancet Oncology, 2010
- Effect of Pazopanib on Tumor Microenvironment and Liposome DeliveryMolecular Cancer Therapeutics, 2010
- Tumor Microvasculature and Microenvironment: Novel Insights Through Intravital Imaging in Pre-Clinical ModelsMicrocirculation, 2010
- Dominant Effect of Antiangiogenesis in Combination Therapy Involving Cyclophosphamide and AxitinibClinical Cancer Research, 2009
- Combination of antiangiogenesis with chemotherapy for more effective cancer treatmentMolecular Cancer Therapeutics, 2008
- Modulation of the antitumor activity of metronomic cyclophosphamide by the angiogenesis inhibitor axitinibMolecular Cancer Therapeutics, 2008
- Enhancement of intratumoral cyclophosphamide pharmacokinetics and antitumor activity in a P450 2B11-based cancer gene therapy modelCancer Gene Therapy, 2007
- Sorafenib in Advanced Clear-Cell Renal-Cell CarcinomaNew England Journal of Medicine, 2007
- Rapid vascular regrowth in tumors after reversal of VEGF inhibitionJournal of Clinical Investigation, 2006